Fate Therapeutics (FATE) Reaches $4.59 After 3.00% Down Move; ENDOCAN CORPORATION (ENDO) Shorts Lowered By 89.29%

November 8, 2017 - By Winifred Garcia

The stock of Fate Therapeutics Inc (NASDAQ:FATE) is a huge mover today! The stock decreased 6.90% or $0.34 during the last trading session, reaching $4.59. About 243,077 shares traded or 1.51% up from the average. Fate Therapeutics Inc (NASDAQ:FATE) has risen 166.12% since November 8, 2016 and is uptrending. It has outperformed by 149.42% the S&P500.The move comes after 9 months negative chart setup for the $191.34M company. It was reported on Nov, 8 by Barchart.com. We have $4.45 PT which if reached, will make NASDAQ:FATE worth $5.74M less.

ENDOCAN CORPORATION (OTCMKTS:ENDO) had a decrease of 89.29% in short interest. ENDO’s SI was 300 shares in November as released by FINRA. Its down 89.29% from 2,800 shares previously. The stock increased 6.99% or $0.001 on November 8, reaching $0.0153. About 110,501 shares traded. Omnicanna Health Solutions Inc (OTCMKTS:ENDO) has 0.00% since November 8, 2016 and is . It has underperformed by 16.70% the S&P500.

Among 4 analysts covering Endo Health (OTCMKTS:ENDO), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Endo Health had 4 analyst reports since September 1, 2015 according to SRatingsIntel. Nomura initiated Omnicanna Health Solutions Inc (OTCMKTS:ENDO) on Tuesday, September 29 with “Buy” rating. The rating was downgraded by Morgan Stanley to “Overweight” on Tuesday, September 1. The rating was reinitiated by Deutsche Bank with “Buy” on Tuesday, September 29. The firm has “Buy” rating by Standpoint Research given on Friday, November 13.

OmniCanna Health Solutions, Inc. offers hemp solutions. The company has market cap of $1.04 million. The Firm utilizes the benefits of hemp, the natural compounds found in the hemp plants, from which, hemp is produced. It currently has negative earnings. The Firm offers quintessential brands across the world, featuring multiple products, including cosmeceuticals and nutraceuticals.

Among 8 analysts covering Fate Therapeutics (NASDAQ:FATE), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Fate Therapeutics has $8 highest and $4 lowest target. $7.33’s average target is 59.69% above currents $4.59 stock price. Fate Therapeutics had 9 analyst reports since October 6, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, September 22 by Roth Capital. The stock of Fate Therapeutics Inc (NASDAQ:FATE) has “Buy” rating given on Thursday, September 22 by TH Capital. The company was maintained on Wednesday, November 1 by BMO Capital Markets. The rating was initiated by Raymond James on Tuesday, October 6 with “Outperform”. Wedbush maintained it with “Outperform” rating and $7 target in Tuesday, November 8 report. As per Friday, December 4, the company rating was initiated by Wells Fargo. BMO Capital Markets initiated Fate Therapeutics Inc (NASDAQ:FATE) rating on Tuesday, April 12. BMO Capital Markets has “Outperform” rating and $4 target. The rating was reinitiated by H.C. Wainwright with “Buy” on Thursday, October 12. The stock of Fate Therapeutics Inc (NASDAQ:FATE) earned “Buy” rating by Leerink Swann on Friday, September 8.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Winifred Garcia




Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: